JAZZ

230.2602.62%
RD

Renee D. Gala

President, CEO & Director

Ms. Renée D. Galá is an Independent Director of DexCom, Inc. from March 6, 2025. She serves as President at Jazz Pharmaceuticals plc since October 2023 and served as Chief Operating Officer at Jazz Pharmaceuticals plc since October 2023 until 2025 and serves as its CEO and Director since August 11, 2025. She was Independent Director of Gossamer Bio, Inc. from December 14, 2018 until June 2024. She joined Jazz as Executive Vice President and Chief Financial Officer in March 2020. From January to June 2019, she served as the Chief Financial Officer of GRAIL, Inc., a private healthcare company focused on the early detection of cancer. She joined the Gossamer Bio, Inc. on December 04, 2018. She served as Chief Financial Officer and Senior Vice President of Theravance Biopharma, Inc. since December 2014 until January 2, 2019.and served as its Treasurer since June 2014 until January 2, 2019. She served as Senior Vice President of Finance at Theravance Biopharma, Inc. since July 2014 and served as its Vice President of Finance since June 2014. From 2006 to June 2014, she held various roles in the finance organization before leading the separation of the biopharmaceutical business (now Theravance Biopharma) from the royalty company, Innoviva, Inc. She has extensive experience in pharmaceutical industry sales, finance, corporate strategy and business development. She served as Vice President of Finance from January 2013 to June 2014. She served as Vice President of Finance at Innoviva, Inc. from January 2013 to May 2014. She joined the Theravance Biopharma, Inc. in June 2014 in connection with the spin-off from Theravance, Inc. after joining Innoviva in June 2006, where she held various roles in the finance organization before being promoted to Vice President of Finance in January 2013. From 2001 to 2006, she worked at Eli Lilly and Company, where she held positions of increasing responsibility in global treasury, pharmaceutical sales and corporate strategy/business development. She spent seven years in the energy industry in the United States and internationally in positions focused on corporate finance, project finance and mergers and acquisitions. She served as an Independent Director of Corcept Therapeutics Incorporated since June 27, 2016 until June 18, 2019. She earned a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.

Positions